An arrhythmia is a problem with the speed or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm. A heartbeat that is too fast is called tachycardia. A heartbeat that is too slow is called bradycardia. Most arrhythmias are harmless, but some can be serious or even life threatening. When the heart rate is too slow, too fast, or irregular, the heart may not be able to pump enough blood to the body. Lack of blood flow can damage the brain, heart, and other organs.
IntriCon Corporation, a designer, developer, manufacturer and distributor of body-worn medical and electronics devices, announced today that it will unveil a prototype of its new Cardiac Diagnostic Monitoring (CDM) device, called the Mobile Patient ECG Telemetry System, or MPETS, at the 2009 American Heart Association (AHA) Scientific Sessions, Nov. 15-17, in Orlando, Fla.
The National Institutes of Health's National Heart, Lung, and Blood Institute will fund a $1 million collaborative study by the Center for Natural Medicine and Prevention at Maharishi University of Management Research Institute and Columbia University Medical Center to determine whether the stress-reducing Transcendental Meditation technique can help patients with coronary heart disease (CHD) prevent future heart attacks, strokes and death.
Nearly 4 million people nationwide suffer from cardiac arrhythmias each year, according to the 2006 U.S. Cardiac Rhythm Management Market report by Frost and Sullivan. About 2.5 million of these cases cannot be treated or controlled through medication alone. Since pharmacological therapies have limited effectiveness, radiofrequency (RF) catheter ablation has emerged as the prominent approach for treating a broad range of arrhythmias.
Myocarditis is an important, and often unrecognized cause of dilated cardiomyopathy (DCM). Several new diagnostic methods, such as cardiac magnetic resonance imaging (MRI), are useful for diagnosing myocarditis, according to a study published in the November 2009 issue of Mayo Clinic Proceedings.
The third quarter of 2009 has followed the same pattern as previous years, with low demand during the summer months and clinics closed for the summer. Production at the end of the quarter has been high with high demand at our clinics.
On Monday, November 2, 2009, Andrea Natale, M.D., F.A.C.C., F.H.R.S., an electrophysiologist and executive medical director of the Texas Cardiac Arrhythmia Institute at St. David's Medical Center, will be the first physician in the United States to perform an ablation procedure to treat a patient with a cardiac arrhythmia, commonly known as an irregular heart rhythm, using the newly FDA-cleared CARTO® 3 Navigation System.
London Genetics Limited, an expert in the use of pharmacogenetics in clinical drug discovery and development, has entered an intensive partnering programme following on from its successful pharmacogenetic conference in September.
A research team at Vanderbilt University has developed an innovative optical system to simultaneously image electrical activity and metabolic properties in the same region of a heart, to study the complex mechanisms that lead to sudden cardiac arrest.
Notice is hereby given that Glancy Binkow & Goldberg LLP has filed a class action lawsuit in the United States District Court for the Northern District of California on behalf of a class consisting of all persons or entities who purchased the securities of Hansen Medical, Inc. between May 1, 2008 and October 18, 2009, inclusive (the “Class Period”).
NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic and services company, today announced that Dr. Sam George, NewCardio's Senior Consultant, will join a distinguished roster of speakers, moderators and panelists at the Cardiac Safety Research Consortium (CSRC) annual meeting in Maryland at the Marriot Bethesda, Pooks Hill location on October 29-30, 2009.
Merck & Co., Inc. announced today that the U.S. Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP) supports the permissive use of GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for boys and young men ages 9 to 26, which means that GARDASIL may be given to males ages 9 to 26 to reduce the likelihood of acquiring genital warts at the discretion of the patient's health care provider.
Hansen Medical, Inc. today announced that it plans to restate its financial statements for the year ended December 31, 2008 and for the quarters ended March 31, 2008, June 30, 2008, September 30, 2008, March 31, 2009 and June 30, 2009 in order to correct certain errors, some of which arose from potential irregularities occurring outside of the accounting department, regarding the timing of revenue recognition on the sale of some of its Sensei® Robotic Catheter Systems.
Sanofi-aventis U.S. announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Elitek (rasburicase) to be used for the initial management of plasma uric acid (PUA) levels in adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis syndrome (TLS) and subsequent elevations of plasma uric acid.
ATS Medical, Inc., manufacturer and marketer of state-of-the-art cardiac surgery products and services announced a number of professional educational opportunities that will focus on ATS Medical products at the upcoming European Association for Cardio-Thoracic Surgeons (EACTS) meeting.
ATS Medical, Inc., manufacturer and marketer of state-of-the-art cardiac surgery products and services, today announced the receipt of CE Mark for the ATS CryoMaze® 10-S Surgical Cryoablation Probe for the treatment of cardiac arrhythmias.
The source and mechanisms underlying the abnormal heart beats that initiate atrial fibrillation (Afib), the most common type of abnormal heart beat, have not been well determined. However, a group of researchers at the University of Pennsylvania, Philadelphia, has now identified a population of cells that are like pigment producing cells in the skin (melanocytes) in the atria of the heart and pulmonary veins of mice and humans and uncovered evidence in mice that these cells contribute to Afib.
Patients who received refurbished pacemakers donated from Detroit area funeral homes survived without complications from the devices, according to a case series reported by the University of Michigan Cardiovascular Center.
Relypsa, Inc., today announced the initiation of patient enrollment in the PEARL-HF study, a Phase 2b clinical trial of the company’s lead compound, RLY5016. A novel potassium binder designed for chronic use, RLY5016 is being evaluated in the prevention and treatment of hyperkalemia, for which there are no current satisfactory treatments.
More than 250,000 deaths occur each year as a result of sudden cardiac arrest (SCA). In fact, SCA claims one life every two minutes, taking more lives each year than breast cancer, lung cancer or AIDS. Yet, according to a recent survey issued by the Heart Rhythm Society, more than 70 percent of Americans not only underestimate the seriousness of SCA, but also believe SCA is a type of heart attack.
Diabetes increases by 26 percent the likelihood that women will develop atrial fibrillation (AF), a potentially dangerous irregular heart rhythm that can lead to stroke, heart failure, and chronic fatigue. These are the findings of a new Kaiser Permanente study, published in the October issue of Diabetes Care, a journal of the American Diabetes Association.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.